CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. This...
- Mechanism
- Curator reviewed
CR002 blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. Diabetic nephropathy, IgA nephropathy, and lupus nephritis are histologically characterized by glomerular mesangial cell proliferation and extracellular matrix accumulation. PDGF-D and its receptors play an important role in the pathogenesis of nephritis, based on their potent induction of mesangial cell proliferation and extracellular matrix accumulation shown both in vitro and in vivo. A fully human monoclonal antibody that neutralizes PDGF-D represents a novel therapeutic approach to block nephritides.
- Primary indication
- Investigated for use/treatment in nephropathy.Curator reviewed
- Also known as
- Human monoclonal antibody against platelet-derived growth factor D
- Code names
- CR-002
Resolves to
What you can answer from here — as of October 19, 2023
Which drugs share a target with CR002, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account